News | September 23, 2008

MammoSite RT Recurrence Rates Comparable to Standard RT

September 24, 2008 - Hologic Inc. released a four-year analysis of the Hologic MammoSite radiation therapy system study, which found that breast cancer recurrence rates following the delivery of accelerated partial breast irradiation with the MammoSite system continue to be comparable to the rates reported with standard radiation therapy.

The study was presented by Peter Beitsch, M.D., of Medical City Dallas Hospital at ASTRO 2008. Beitsch and his colleagues analyzed data from patients enrolled in the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial.

The researchers reported that their analysis of the overall registry population with a median follow-up of 36 months showed a three-year actuarial rate of Ipsilateral Breast Tumor Recurrence (IBTR) of 2.15 percent. Other follow-up results were also positive (0.26 percent three-year actuarial rate for axillary recurrences and 0.74 percent three-year actuarial rate for new primary cancers).

In a subset of patients (the first 400 treated), 44-month follow-up data was captured and a 93.9 percent survival rate was reported (88.9 percent disease-free and 100 percent cancer-specific). The researchers concluded that treatment with the MammoSite system resulted in low IBTR, low axillary recurrence, and acceptable cancer specific survival.

The MammoSite device is a balloon catheter that is inserted into the cavity created by a lumpectomy (the surgical removal of a breast tumor). The MammoSite radiation therapy system delivers radiation from inside the lumpectomy cavity over a course of five days. The device targets radiation to the area where tumors are most likely to recur, while reducing exposure to healthy tissue.

For more information: www.hologic.com

Related Content

Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation
150-Year-Old Drug Might Improve Radiation Therapy for Cancer
News | Radiation Therapy | November 02, 2018
November 2, 2018 — A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more